In prostate cancer, it has been shown that P2Y2R cooperates with EGFR to promote cell invasion and metastasis through the ERK1/2 pathway, suggesting a therapeutic possibility using purinergic blockers to treat this type of cancer (Li et al., 2015). This evidence concerns the gene MAPK3 and prostate carcinoma.